Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Celgene Corporation

Share:
Related CELG
American Air, Bank Of America, Celgene, Netflix: Fast Money Picks For July 12
Merck Falls As FDA Puts Hold On 3 Keytruda Myeloma Studies
Biotechs On A Hot Streak, And Could Be 'Cooking With Gas' (Investor's Business Daily)

In a report published Monday, Jefferies & Company reiterated its Buy rating on Celgene Corporation (NASDAQ: CELG), and raised its price target from $91.00 to $94.00.

Jefferies noted, “CELG announced Abraxane met its overall survival primary endpoint in its Phase 3 pancreatic cancer study. We have long considered this indication to be risky and upside to our valuation. Adding pancreatic cancer to our valuation raises our price target from $91 to $94.”

Celgene Corporation closed on Friday at $71.50.

Latest Ratings for CELG

DateFirmActionFromTo
Jul 2017JefferiesAssumesBuy
Jun 2017BTIG ResearchDowngradesBuyNeutral
Jun 2017Leerink SwannUpgradesMarket PerformOutperform

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (CELG)

View Comments and Join the Discussion!